Clinical Trials Logo

Spinocerebellar Ataxias clinical trials

View clinical trials related to Spinocerebellar Ataxias.

Filter by:

NCT ID: NCT04399265 Recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3

Start date: February 24, 2020
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3. A total of 40 participants with SCA3 will be recruited, with 20 participants to be administered with trehalose while another 20 participants to be administered with a maltose placebo.

NCT ID: NCT04301284 Withdrawn - Clinical trials for Spinocerebellar Ataxias

Study of CAD-1883 for Spinocerebellar Ataxia

Synchrony-1
Start date: June 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.

NCT ID: NCT04297891 Recruiting - Spastic Ataxia Clinical Trials

Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias

SPAX-PBP
Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to determine the clinical spectrum and natural progression of Spastic Ataxias (SPAX) and related disorders in a prospective multicenter natural history study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the genetic etiology and molecular mechanisms of these diseases.

NCT ID: NCT04288128 Completed - Clinical trials for Spinocerebellar Ataxia Type 2

Integrated Functional Evaluation of the Cerebellum

CERMOI
Start date: May 28, 2020
Phase:
Study type: Observational

One of the main objectives of this project is to validate potential biological, clinical and/or imaging biomarkers in SCA patients through a multimodal assessment, for future ASOs trials.

NCT ID: NCT04268147 Active, not recruiting - Friedreich Ataxia Clinical Trials

Instrumented Data Exchange for Ataxia Study

IDEA
Start date: June 1, 2019
Phase:
Study type: Observational

This research study is testing body-worn sensors to measure movement during simple tests of coordination, in order to evaluate the progression and severity of ataxia.

NCT ID: NCT04231487 Recruiting - Parkinson Disease Clinical Trials

Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders

Start date: June 27, 2019
Phase:
Study type: Observational

The purpose of the research is to better understand the motor behavior of individuals in health and disease. The specific purpose of this project is to identify if we can utilize a smartphone to diagnose different movement disorders and monitor their symptoms. A. Objectives 1. Estimate symptom severity of Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), Primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and Functional movement disorders (FMD) using a smartphone-based application 2. Differentiate individuals with the different movement disorders from healthy controls based on features from the smartphone data 3. Differentiate individuals with a specific movement disorder from people with other movement disorders based on features from the smartphone data B. Hypotheses / Research Question(s) We hypothesize that we can estimate the severity of symptoms using a smartphone application and that, using those estimates, we can differentiate individuals with movement disorders from healthy controls and from people with other movement disorders.

NCT ID: NCT04229823 Active, not recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD

BIGPRO
Start date: March 28, 2017
Phase:
Study type: Observational

The study will consist of a prospective observation of subjects in a natural history design. Disease progression will be monitored through clinical scales and video-oculography. Participants will be stratified in three groups: ataxic carriers, pre-ataxic carriers and non-carriers (controls). The following clinical scales will be applied in all subjects at baseline and at months 12 and 24: SARA, SCAFI, CCFS, NESSCA, INAS and ICARS. Oculomotor function will be registered using video-oculography (EyeSeeCam, InterAcoustics) at the same time points. Progression rates, effect sizes and responsiveness to change will be established for all parameters and results will be compared between candidate biomarkers.

NCT ID: NCT04153110 Completed - Clinical trials for Multiple System Atrophy

Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia

SCA02
Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Neurodegenerative cerebellar ataxias represent a group of disabling disorders which currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study followed by an open-label phase, the investigators will evaluate whether a repetition of two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS, after a three months interval, may further outlast clinical improvement in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

NCT ID: NCT04107740 Completed - Clinical trials for Spinocerebellar Degeneration

C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration

Start date: March 4, 2019
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of C-Trelin OD Tablet 5mg(Taltirelin Hydrate) in Multicenter, randomized, double-blind, placebo-controlled clinical trial in patients with ataxia induced by spinocerebellar degeneration.

NCT ID: NCT04098211 Active, not recruiting - Clinical trials for Neuronal Ceroid-Lipofuscinoses

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients

Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTPP1 or atypical tripeptidyl peptidase deficiency) have and how they change over time.